Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) EBT (2016 - 2025)

Historic EBT for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to $15.1 million.

  • Anaptysbio's EBT rose 14600.47% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.6 million, marking a year-over-year increase of 4895.78%. This contributed to the annual value of -$145.2 million for FY2024, which is 1124.23% up from last year.
  • Latest data reveals that Anaptysbio reported EBT of $15.1 million as of Q3 2025, which was up 14600.47% from -$38.6 million recorded in Q2 2025.
  • Anaptysbio's 5-year EBT high stood at $15.1 million for Q3 2025, and its period low was -$46.7 million during Q2 2024.
  • For the 5-year period, Anaptysbio's EBT averaged around -$28.0 million, with its median value being -$31.4 million (2022).
  • Its EBT has fluctuated over the past 5 years, first plummeted by 612191.14% in 2022, then skyrocketed by 14600.47% in 2025.
  • Quarter analysis of 5 years shows Anaptysbio's EBT stood at -$31.1 million in 2021, then grew by 28.8% to -$22.1 million in 2022, then plummeted by 90.72% to -$42.2 million in 2023, then surged by 48.38% to -$21.8 million in 2024, then surged by 169.36% to $15.1 million in 2025.
  • Its EBT was $15.1 million in Q3 2025, compared to -$38.6 million in Q2 2025 and -$39.3 million in Q1 2025.